#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13654	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2056	657.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1670	1670	T	741	T	673	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13654	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2056	657.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1404	1404	C	890	C,G	828,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13654	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2056	657.6	0	HET	.	.	.	C607T,A	.	607	607	C	827	827	C	815	C,T,A	619,154,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24348	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3410	709.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1584	1584	A	794	A,G	744,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24348	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3410	709.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2218	2218	C	801	C,T	733,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24348	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3410	709.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2292	2292	A	798	A	753	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24348	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3410	709.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2844	2844	C	758	C,A	725,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1922	folP	855	855	100.0	folP.l15.c4.ctg.1	1528	125.1	1	SNP	p	R229S	1	.	.	685	687	AGC	995	997	AGC	193;192;194	A;G;C	176;175;175	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4980	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3463	143.3	1	SNP	p	S91F	1	.	.	271	273	TTC	635	637	TTC	196;198;196	T;T;C,T	180;182;177,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4980	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3463	143.3	1	SNP	p	D95G	1	.	.	283	285	GGC	647	649	GGC	204;201;202	G;G;C,T	188;191;190,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4980	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3463	143.3	1	SNP	p	G95N	0	.	.	283	285	GGC	647	649	GGC	204;201;202	G;G;C,T	188;191;190,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1572	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1210	128.8	1	SNP	p	G45D	0	.	.	133	135	GGC	445	447	GGC	209;209;212	G;G;C	195;195;194	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	814	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1013	79.7	0	.	n	.	0	A197.	DEL	197	197	A	595	595	A	187	A	181	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4842	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2936	164.2	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1487	1489	GTC	184;184;184	G;T;C	173;165;171	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4842	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2936	164.2	1	SNP	p	D86N	0	.	.	256	258	GAC	593	595	GAC	226;226;226	G;A;C	212;205;215	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4842	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2936	164.2	1	SNP	p	S87R	1	.	.	259	261	CGT	596	598	CGT	228;222;224	C;G;T	215;209;208	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4842	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2936	164.2	1	SNP	p	R87I	0	.	.	259	261	CGT	596	598	CGT	228;222;224	C;G;T	215;209;208	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4842	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2936	164.2	1	SNP	p	R87W	0	.	.	259	261	CGT	596	598	CGT	228;222;224	C;G;T	215;209;208	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4842	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2936	164.2	1	SNP	p	S88P	0	.	.	262	264	TCC	599	601	TCC	224;226;227	T;C;C	213;218;216	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4200	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2596	161.3	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1314	1316	TGC	213;211;212	T;G;C	199;198;198	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4200	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2596	161.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1524	1526	GGC	222;216;211	G;G;C	203;197;192	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1244	1246	GCA	227;226;233	G;C;A	216;211;222	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1247	1249	ATC	233;232;235	A;T;C	222;221;223	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1259	1261	GTG	230;231;229	G;T;G,C	218;218;215,1	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1259	1261	GTG	230;231;229	G;T;G,C	218;218;215,1	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1763	1765	ACC	217;217;219	A;C;C,A,T	197;203;203,1,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1817	1819	GCG	197;198;197	G;C,G;G	180;157,2;163	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1817	1819	GCG	197;198;197	G;C,G;G	180;157,2;163	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1940	1942	GGC	216;213;211	G;G;C,T	197;196;193,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1949	1951	GGC	211;213;212	G;G;C	192;193;192	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3924	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2446	159.6	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1967	1969	TCG	207;206;199	T,G;C;G	139,6;164;159	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5406	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3087	174.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1513	1515	CCG	213;216;218	C,T;C,T;G	189,1;199,1;197	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2166	porA	1146	1146	99.56	porA.l15.c17.ctg.1	1536	138.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	412	412	C	149	C	135	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	274	porB1a	984	112	91.96	porB1a.l6.c17.ctg.1	862	17.2	0	.	p	.	0	M18T	NONSYN	52	54	ATG	727	729	ACG	67;68;67	A;C;G	65;66;64	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	274	porB1a	984	112	91.96	porB1a.l6.c17.ctg.1	862	17.2	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	769	771	CAA	37;33;32	C;A;A	34;30;29	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	274	porB1a	984	112	91.96	porB1a.l6.c17.ctg.1	862	17.2	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	775	777	TAC	22;18;15	T;A;C	22;18;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	436	438	GAA	232;233;231	G;A;A	215;214;213	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	724	726	GAT	220;217;219	G;A;T	204;201;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	847	849	TCA	216;219;217	T;C;A	208;211;208	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	0	.	p	.	0	K207_K208del	DEL	619	619	A	942	942	T	217	T	207	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	967	969	GTC	237;237;239	G;T;C	218;217;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1297	1299	GCA	185;184;185	G;C,T;A	177;174,1;177	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	1	SNP	p	G120K	1	.	.	358	360	AAG	682	684	AAG	231;231;231	A;A;G	217;215;216	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	1	SNP	p	D121N	0	.	.	361	363	GAC	685	687	GAC	226;227;226	G;A;C	211;213;213	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2588	porB1b	1047	1047	98.47	porB1b.l15.c4.ctg.1	1505	170.8	1	SNP	p	A121D	1	.	.	361	363	GAC	685	687	GAC	226;227;226	G;A;C	211;213;213	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9424	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4820	194.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2020	2022	AAT	215;216;217	A;A;T	203;204;205	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1062	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1095	96.4	1	SNP	p	V57M	1	.	.	169	171	ATG	581	583	ATG	246;244;244	A;T;G	226;224;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
